TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39073518

Group type: COMPARATOR
Intervention: Group Intervention - Collective Advocacy - Individual Counseling (GI-CA-IC) sequence
Number of subjects: 940

Group type: COMPARATOR
Intervention: Intervention package conducted simultaneously at pilot site
Number of subjects: 940

Group type: COMPARATOR
Intervention: Collective Advocacy - Individual Counseling - Group Intervention (CA-IC-GI) sequence
Number of subjects: 940
Study: 39073523

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 39073574

Group type: EXPERIMENTAL
Intervention: sarilumab + methotrexate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sarilumab + csDMARDs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: sarilumab monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (csDMARDs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CDAI scores
Number of subjects: 30
Study: 39073577

Group type: EXPERIMENTAL
Intervention: SAR monotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SAR + csDMARDs
Number of subjects: 91
Study: 39073580

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 76
Study: 39073712

Group type: EXPERIMENTAL
Intervention: risankizumab
Number of subjects: 42

Group type: COMPARATOR
Intervention: guselkumab and mirikizumab
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: age
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: disease duration
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: high-risk group (risk value > 1.5)
Number of subjects: 42
Study: 39073796

Group type: EXPERIMENTAL
Intervention: Consult for Addiction Treatment and Care in Hospitals (CATCH) program
Number of subjects: 2315

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 2315
Study: 39073799

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg intravenous every 3 weeks for up to nine treatment cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline scores (before treatment)
Number of subjects: 0
Study: 39073812

Group type: EXPERIMENTAL
Intervention: iPCIT (internet-based parent-child interaction training)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Referrals as usual (control)
Number of subjects: 71
Study: 39073822

Group type: EXPERIMENTAL
Intervention: Staged, bilateral focused ultrasound thalamotomy
Number of subjects: 51
Study: 39073823

Group type: EXPERIMENTAL
Intervention: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services.
Number of subjects: 19113

Group type: EXPERIMENTAL
Intervention: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among Black individuals.
Number of subjects: 19113

Group type: EXPERIMENTAL
Intervention: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among White individuals.
Number of subjects: 19113
Study: 39073834

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) via colonoscopy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo via colonoscopy
Number of subjects: 45
Study: 39074277

Group type: EXPERIMENTAL
Intervention: Free phone mount to facilitate hands-free use
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Education about the risks of handheld phone use
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Other arms received education about risks and additional interventions (not specified in the abstract)
Number of subjects: 1653
Study: 39074480

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 253

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 253
Study: 39074504

Group type: EXPERIMENTAL
Intervention: Structured informational pamphlet on CRC screening and printed guide for FIT kit usage
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 37
Study: 39074931

Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg) and Etoposide (50 mg)
Number of subjects: 29
Study: 39074964

Group type: EXPERIMENTAL
Intervention: preHEART score
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: HEART score
Number of subjects: 823

Group type: COMPARATOR
Intervention: T-MACS
Number of subjects: 823

Group type: COMPARATOR
Intervention: POC-troponin measurement alone
Number of subjects: 823
Study: 39074992

Group type: EXPERIMENTAL
Intervention: Genetic testing with results disclosure and genetic counselling
Number of subjects: 10510

Group type: EXPERIMENTAL
Intervention: Genetic testing for GBA1
Number of subjects: 10510

Group type: EXPERIMENTAL
Intervention: Genetic testing for LRRK2
Number of subjects: 10510

Group type: EXPERIMENTAL
Intervention: Genetic testing for PRKN
Number of subjects: 10510

Group type: EXPERIMENTAL
Intervention: Genetic testing for SNCA
Number of subjects: 10510

Group type: EXPERIMENTAL
Intervention: Genetic testing for PINK1, PARK7, or VPS35 combined
Number of subjects: 10510

Group type: EXPERIMENTAL
Intervention: Genetic testing for multiple genes
Number of subjects: 10510
Study: 39075139

Group type: EXPERIMENTAL
Intervention: Highest quartile of inflammation composite score (Q4)
Number of subjects: 10044
Study: 39075156

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham manual therapy (control)
Number of subjects: 104
Study: 39075268

Group type: EXPERIMENTAL
Intervention: PIM (Patient Aligned Care Team Intensive Management)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: PIM
Number of subjects: 456

Group type: COMPARATOR
Intervention: Control (not referred to PIM)
Number of subjects: 456
Study: 39075274

Group type: EXPERIMENTAL
Intervention: Difamilast 0.3% ointment applied twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Difamilast 0.3% or 1% ointment applied based on existing symptoms
Number of subjects: 41
Study: 39075354

Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control (no vasopressor administration)
Number of subjects: 301
Study: 39075369

Group type: EXPERIMENTAL
Intervention: Patients who developed AKI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who did not develop AKI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients transferred from the Medical Floor who developed AKI
Number of subjects: 0
Study: 39075454

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham-taVNS
Number of subjects: 0
Study: 39075465

Group type: EXPERIMENTAL
Intervention: YSLQQ intervention group (n=526)
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Control group (n=654)
Number of subjects: 1180
Study: 39075484

Group type: EXPERIMENTAL
Intervention: Aspirin cessation
Number of subjects: 6103

Group type: COMPARATOR
Intervention: Aspirin continuation
Number of subjects: 6103
Study: 39075506

Group type: EXPERIMENTAL
Intervention: Healthcare worker HTN and CVD care training plus long-term practice facilitation, electronic health record (EHR) documentation of key indicators and use of reminders, and use of treatment partners to provide social support.
Number of subjects: 4652

Group type: EXPERIMENTAL
Intervention: InterCARE model (if successful)
Number of subjects: 4652
Study: 39075531

Group type: EXPERIMENTAL
Intervention: Docetaxel-radiotherapy (Doc-RT)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Cisplatin-radiotherapy (Cis-RT)
Number of subjects: 224
Study: 39075535

Group type: EXPERIMENTAL
Intervention: ENDS (BIDI)
Number of subjects: 25
Study: 39075543

Group type: EXPERIMENTAL
Intervention: Oxygen supplementation during altitude exposure
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ambient air supplementation during altitude exposure
Number of subjects: 36
Study: 39075587

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus vitamin C
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 100
Study: 39075590

Group type: EXPERIMENTAL
Intervention: Train-the-trainer (TTT) strategy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Expert consultation condition
Number of subjects: 24
Study: 39075617

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) eating pattern with supportive positive affect and mindful eating skills
Number of subjects: 17
Study: 39075620

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 945

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 945
Study: 39075732

Group type: EXPERIMENTAL
Intervention: SA IOL (IC-8 small aperture intraocular lens) targeted to -0.75 D
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SA IOL (IC-8 small aperture intraocular lens)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: SA IOL (IC-8 small aperture intraocular lens) with higher preoperative corneal astigmatism (1.0-1.5 D)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Monofocal/monofocal toric IOLs targeted to plano (control group)
Number of subjects: 453
Study: 39075925

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 568
Study: 39075931

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Metabolically unhealthy obesity (MUO)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Individual metabolic syndrome (MS) markers
Number of subjects: 84
Study: 39075946

Group type: EXPERIMENTAL
Intervention: Facilitated tucking + expressed breast milk
Number of subjects: 175

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 175
Study: 39076099

Group type: EXPERIMENTAL
Intervention: Trastuzumab biosimilar (AryoTrust) administered every 3 weeks for nine cycles
Number of subjects: 597
Study: 39076170

Group type: EXPERIMENTAL
Intervention: Carrying pathogenic/likely pathogenic (P/LP) variants
Number of subjects: 3071

Group type: COMPARATOR
Intervention: Carrying variants of uncertain significance (VUS)
Number of subjects: 3071

Group type: COMPARATOR
Intervention: Non-variant group
Number of subjects: 3071
Study: 39076175

Group type: EXPERIMENTAL
Intervention: DuraGraft©
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study: 39076220

Group type: EXPERIMENTAL
Intervention: SYNTAX score II (SS-II)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SYNTAX score 2020 (SS-2020)
Number of subjects: 200
Study: 39076222

Group type: EXPERIMENTAL
Intervention: Tocovid capsules
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo containing palm superolein
Number of subjects: 250
Study: 39076324

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE) guidance
Number of subjects: 363

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE) guidance
Number of subjects: 363
Study: 39076386

Group type: EXPERIMENTAL
Intervention: High Cystatin C/Left Ventricular Ejection Fraction Ratio (CLR) group
Number of subjects: 14733
Study: 39076427

Group type: EXPERIMENTAL
Intervention: Fibrinogen-to-albumin ratio (FAR)
Number of subjects: 66761
Study: 39076438

Group type: EXPERIMENTAL
Intervention: Visceral Adiposity Tissue Index (VATI)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Triglyceride-Glucose (TyG) index
Number of subjects: 542
Study: 39076448

Group type: EXPERIMENTAL
Intervention: Physical activity measured with accelerometer (Actigraph GTX3)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Sedentary time measured with accelerometer (Actigraph GTX3)
Number of subjects: 501
Study: 39076483

Group type: EXPERIMENTAL
Intervention: Thin-cap fibroatheroma (TCFA), small luminal area, and large plaque burden (PB)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of TCFA and minimal lumen area (MLA)
Number of subjects: 86
Study: 39076545

Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q1 (lowest CALLY index)
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q2
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q3
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: CALLY index quartile Q4 (highest CALLY index)
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: All-cause mortality (ACM)
Number of subjects: 3799

Group type: EXPERIMENTAL
Intervention: Cardiac mortality (CM)
Number of subjects: 3799
Study: 39076569

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) applied on the left upper limb twice daily, starting three days before DCB implantation.
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Control group (no RIPC)
Number of subjects: 653
Study: 39076593

Group type: EXPERIMENTAL
Intervention: SHR-1905 (50, 100, 200, 400, and 600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SHR-1905
Number of subjects: 0
Study: 39076624

Group type: EXPERIMENTAL
Intervention: Volatile anesthesia (VA) - sevoflurane, isoflurane, or desflurane
Number of subjects: 1586

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 1586
Study: 39076658

Group type: EXPERIMENTAL
Intervention: 1,5-anhydroglucitol (1,5-AG) levels
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group (MACCEs-free group)
Number of subjects: 270
Study: 39076670

Group type: EXPERIMENTAL
Intervention: Prediction model based on Lasso regression and multivariate logistic regression
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Factors associated with high risk of thromboembolism
Number of subjects: 338
Study: 39076703

Group type: EXPERIMENTAL
Intervention: DynamX Bioadaptor
Number of subjects: 50
Study: 39076700

Group type: EXPERIMENTAL
Intervention: Q4 group of HF patients
Number of subjects: 3114

Group type: COMPARATOR
Intervention: Q1 and Q3 groups of HF patients
Number of subjects: 3114
Study: 39076716

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) classifier
Number of subjects: 2108

Group type: COMPARATOR
Intervention: Traditional APPROACH risk score
Number of subjects: 2108

Group type: EXPERIMENTAL
Intervention: Machine learning approaches
Number of subjects: 2108

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 2108
Study: 39076742

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) mode
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA) mode
Number of subjects: 31

Group type: COMPARATOR
Intervention: Pressure-Regulated Volume Control (PRVC) mode
Number of subjects: 31
Study: 39076748

Group type: EXPERIMENTAL
Intervention: Angiography-derived index of microcirculatory resistance (angio-IMR) calculated based on computed flow and pressure dynamic principles.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Follow-up for major adverse cardiovascular events (MACEs) including all-cause death, non-fatal myocardial infarction, target vessel revascularization (TVR), and stroke.
Number of subjects: 118
Study: 39076751

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 50
Study: 39076879

Group type: EXPERIMENTAL
Intervention: HIIT combined with strength training
Number of subjects: 44

Group type: COMPARATOR
Intervention: HIIT
Number of subjects: 44
Study: 39076944

Group type: EXPERIMENTAL
Intervention: CACS-weighted clinical likelihood (CACS-CL) model with cutoff of 5%
Number of subjects: 6689

Group type: EXPERIMENTAL
Intervention: CACS-weighted clinical likelihood (CACS-CL) model with cutoff of 15%
Number of subjects: 6689
Study: 39076951

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72
Study: 39077002

Group type: EXPERIMENTAL
Intervention: Regulatory T cell (Treg)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Peak value of Creatine Kinase MB (pCKMB)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Left ventricular end-systolic diameter (LVESD)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Integrated 4-marker panel (Treg, pCKMB, hsCRP, LVESD)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Integrated 4-marker panel added to baseline risk model
Number of subjects: 182
Study: 39077009

Group type: EXPERIMENTAL
Intervention: Culprit vessel size (small, medium, large)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Different plaque phenotypes
Number of subjects: 404
Study: 39077018

Group type: EXPERIMENTAL
Intervention: Poorly regulated diabetes
Number of subjects: 309

Group type: COMPARATOR
Intervention: Well-regulated diabetes
Number of subjects: 309

Group type: COMPARATOR
Intervention: Non-diabetes
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Plasma glycated hemoglobin (HbA1c) level
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Systemic inflammatory mediators
Number of subjects: 309
Study: 39077077

Group type: EXPERIMENTAL
Intervention: Intermediate hyperglycemia
Number of subjects: 14585

Group type: COMPARATOR
Intervention: Normal glycemia
Number of subjects: 14585
Study: 39077099

Group type: EXPERIMENTAL
Intervention: Coronary sinus reducer (CSR) implantation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 24
Study: 39077135

Group type: EXPERIMENTAL
Intervention: 7-Fr Glidesheath Slender
Number of subjects: 504

Group type: COMPARATOR
Intervention: Conventional 7-Fr Cordis sheath
Number of subjects: 504
Study: 39077398

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined training (HIIT + strength training)
Number of subjects: 13
Study: 39077419

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase (MPO) levels in HFpEF patients
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High levels of MPO in HFpEF patients
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Association between oxidative stress and vascular stiffness
Number of subjects: 55
Study: 39077421

Group type: COMPARATOR
Intervention: FFR-deferred vessels
Number of subjects: 1305

Group type: COMPARATOR
Intervention: FFR-revascularized vessels
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Angio-revascularized vessels
Number of subjects: 1305

Group type: COMPARATOR
Intervention: FFR-guided vessels (both FFR-revascularized and FFR-deferred)
Number of subjects: 1305
Study: 39077424

Group type: EXPERIMENTAL
Intervention: 3D printing technology for transcatheter mitral valve interventions (TMVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bench test simulation and multi-material printing
Number of subjects: 0
Study: 39077475

Group type: EXPERIMENTAL
Intervention: Increased left ventricular end-diastolic diameter (LVEDD)
Number of subjects: 33147

Group type: EXPERIMENTAL
Intervention: LVEDD measurements
Number of subjects: 33147
Study: 39077494

Group type: EXPERIMENTAL
Intervention: NOACs
Number of subjects: 196

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 196
Study: 39077519

Group type: EXPERIMENTAL
Intervention: Modified GRACE scoring system (combining B-type natriuretic peptide precursor and traditional GRACE score)
Number of subjects: 4561

Group type: COMPARATOR
Intervention: Traditional GRACE scoring system
Number of subjects: 4561
Study: 39077543

Group type: EXPERIMENTAL
Intervention: eXtreme Gradient Boosting (XGBoost) model
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Baseline information
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Statistical analysis and SHAP plot visualization methods
Number of subjects: 400
Study: 39077558

Group type: EXPERIMENTAL
Intervention: High GAR group
Number of subjects: 14994

Group type: COMPARATOR
Intervention: Low GAR group
Number of subjects: 14994
Study: 39077587

Group type: EXPERIMENTAL
Intervention: CHARIS algorithms for quantitative and localization analysis of thrombus burden
Number of subjects: 341
Study: 39077655

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 4394
Study: 39077768

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control (nonrandomized groups)
Number of subjects: 251
Study: 39077886

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every four weeks
Number of subjects: 630

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 630

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every two weeks (BE OPTIMAL only)
Number of subjects: 630
Study: 39077889

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 130
Study: 39077892

Group type: EXPERIMENTAL
Intervention: Clinical candidate intervention
Number of subjects: 0
Study: 39077906

Group type: EXPERIMENTAL
Intervention: Itepekimab (300 mg q2w and q4w doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itepekimab alone and in combination with dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39077939

Group type: COMPARATOR
Intervention: Vitamin D supplementation
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Vitamin D + calcium supplementation
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Vitamin D + calcium + other vitamins and minerals supplementation
Number of subjects: 2313
Study: 39078289

Group type: EXPERIMENTAL
Intervention: Clo/ara-C (Clofarabine + Ara-C)
Number of subjects: 390

Group type: COMPARATOR
Intervention: ACS10 score-based tailored induction (Clo/ara-C for low and LDAC for high-ACS10 score groups)
Number of subjects: 390
Study: 39078403

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39078582

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream applied twice daily for up to 52 weeks
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Number of subjects: 652
Study: 39078584

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dupilumab 300 mg
Number of subjects: 0